Xyzagen Expands Services, Provides Drug Stability Capabilities
Pittsboro, NC – February 20, 2024 – Xyzagen, Inc., a leading pharmacokinetics consultancy and contract research organization (CRO), expanded its service offerings with the introduction of early discovery drug stability capabilities. This expansion aimed to support the growing needs of pharmaceutical companies in ensuring their discovery formulations and API are stable in support of their future GLP toxicology studies and ongoing non-GLP in vivo pharmacology and pharmacokinetic studies.
The new drug stability services allow Xyzagen to support early phase stability studies that monitor the effects of environmental factors, such as temperature, humidity, and light, on pharmaceutical products. This addition complements Xyzagen’s existing portfolio, which includes bioanalysis and in vivo pharmacology and pharmacokinetics. By enhancing its capabilities in stability testing, Xyzagen further solidified its position as a trusted partner for companies seeking early phase cost effective reliable solutions for early drug discovery.
“Expanding our services to include drug stability testing is a significant milestone for Xyzagen,” said Christopher Crean, CEO and Founder of Xyzagen. “This capability strengthens our commitment to providing end-to-end discovery solutions for our clients and reinforces our dedication to supporting the pharmaceutical industry at the early stage of development.”
About Xyzagen, Inc.
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late stage clinical noncompartmental PK, PopPK and Quantitative Medicine. Our knowledge in pharmacology and pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. Xyzagen’s a boutique organization which allows small clients to work directly and strategically with experts during their drug development programs.
Media Contact:
Christopher Crean
Founder & CEO, Xyzagen, Inc.
Phone: (919) 762-2072
Email: [email protected]
